Jubilant HollisterStier Approved for Manufacture of Lantheus' DEFINITY Vial

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

Lantheus Medical Imaging has received U.S. Food and Drug Administration (FDA) approval for a Supplemental New Drug Application (sNDA) that allows Jubilant HollisterStier (JHS) to become a new manufacturing site for DEFINITY Vial, an ultrasound contrast agent.

JHS will replace Ben Venue Laboratories (BVL) as the primary manufacturer of DEFINITY as BVL exits the contract manufacturing services business over the next several years. Lantheus also has contracts with JHS for the manufacture and supply of Cardiolite and Neurolite, two technetium-based isotopes used in SPECT imaging.

Lantheus is currently working to secure additional suppliers for its key products as part of its ongoing supply chain diversification strategy.